SAB-142: Audience

SAB-142 is a disease-modifying immunotherapy developed by SAB Biotherapeutics aimed at delaying the onset and progression of type 1 diabetes (T1D). It addresses the underlying cause of T1D by targeting the over-reactive immune response that attacks insulin-producing beta cells in the pancreas.